CliffBio
small molecule

DEXACIDIN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEXACIDIN
Active ingredientDEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Strength0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 1984
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.